Press Releases

Samsung BIO Insight

Optimized facilities for flexible, agile manufacturing

Optimized facilities for flexible, agile manufacturing

 

Biopharmaceutical manufacturing requires specialized facilities that meet strict regulatory standards to ensure product quality and patient safety. These facilities must be versatile enough to handle unique and complex molecules, including multispecific antibodies, antibody-drug conjugates, and mRNA therapies. Each product type requires highly compatible equipment, environmental controls, and manufacturing processes, adding complexity to facility design and construction.


Samsung Biologics aims to build flexible and efficient facilities to meet each client’s needs. “Our goal is to help our clients achieve faster time to market and reduce costs while maintaining the highest standards of quality,” says Junghyun Bak, Director of Engineering Planning at Samsung Biologics. “By using advanced engineering tools and leveraging our extensive experience, we streamline the entire facility development process.”



Proven track record and expertise in facility design and engineering

From years of experience, Samsung Biologics has refined its facility design methodology to minimize inefficiencies, reduce costs, and shorten project timelines. Our comprehensive strategy encompasses all facility development phases—from design and construction to operational readiness—ensuring each manufacturing site is ready to efficiently produce high-quality biopharmaceutical products.


Samsung Biologics successfully completed four large-scale plants, demonstrating a strong ability to manage complex projects effectively. The company is currently building Plant 5, the first facility of Bio Campus II, whichwill be operational by April 2025. The construction timeline is expected to be approximately 30% shorter than the 35 months taken to complete Plant 3, which has the same capacity. The shortened timeline underscores the company’s expertise and commitment to expanding manufacturing capabilities to meet diverse and immediate client needs.


plant1(30kL) : 25months, plant2(154kL) : 29months, plant3(180kL) : 34months, plant4(240kL) : 31months, plant5(180kL | Operational in April 2025) : 24months


Advanced engineering and estimation tools are crucial for meticulously planning facility development, including material and utility requirements, project timelines, and cost estimates. Using these tools and a project management information system for real-time management, Samsung Biologics significantly reduced the risk of cost overruns and delays, allowing for efficient resource allocation, benefiting the company and our clients.


Samsung Biologics continuously improves facility design, construction, and validation methodologies. Each new plant implements best practices and the latest regulatory requirements, optimized for operational excellence. The Engineering, Procurement, Construction, and Validation(EPCV) Team uses historical data from past projects for feasibility studies, gap analyses, and capital expenditure estimations to deliver customized solutions that meet clients’ needs.

 


Innovative strategies for enhancing efficiency

Samsung Biologics will adopt the standardized design at Bio Campus II, starting with Plant 5, to enable seamless scaling across multiple projects. This modular manufacturing model will accelerate construction timelines, enhance operational efficiency, and allow for agile adaptation to varying project requirements. By replicating proven designs and processes, Samsung Biologics can scale operations efficiently while maintaining the highest standards of quality and reliability. 


 

To be more flexible and efficient, Samsung Biologics employs an optimized downstream processing strategy that enables the simultaneous processing of multiple batches or different products. This is especially efficient for complex molecules or products that require longer processing times. Minimizing bottlenecks and ensuring continuous operation enables agile responses to changing production demands, maximizing throughput while ensuring quality and speed to market for clients.


“Having manufactured thousands of batches and developed hundreds of products, we have built a robust knowledge base that helps us anticipate challenges and develop cost-effective solutions,” explains Yujin Kim, an engineer in our Engineering Planning Group at Samsung Biologics. “Our focus on continuous improvement and innovation ensures that we are always advancing our capabilities to better support clients.” 

 


Commitment to quality and client success

Samsung Biologics emphasizes quality excellence as well as client satisfaction, and we continue to build on our facility development capabilities to exceed industry standards. The company is committed to providing clients with the utmost flexibility and reliability so they can quickly bring life-saving medicines to patients worldwide.


Samsung Biologics remains steadfast in its commitment to enhance manufacturing capabilities and provide innovative technological solutions. Additionally, the company will closely monitor its clients’ diverse needs and evolving market trends for timely capacity expansion and tailored services.


For more information about Samsung Biologics’ biomanufacturing capabilities, please contact us

 

Related contents

Samsung BIO Insight Accelerating success in biologics manufacturing | Tech transfer

Samsung BIO Insight Scaling Up Quality and Flexibility with Trusted Partnership

Brochure Plant 5

Optimized facilities for flexible, agile manufacturing


Biopharmaceutical manufacturing requires specialized facilities that meet strict regulatory standards to ensure product quality and patient safety. These facilities must be versatile enough to handle unique and complex molecules, including multispecific antibodies, antibody-drug conjugates, and mRNA therapies. Each product type requires highly compatible equipment, environmental controls, and manufacturing processes, adding complexity to facility design and construction.


Samsung Biologics aims to build flexible and efficient facilities to meet each client’s needs. “Our goal is to help our clients achieve faster time to market and reduce costs while maintaining the highest standards of quality,” says Junghyun Bak, Director of Engineering Planning at Samsung Biologics. “By using advanced engineering tools and leveraging our extensive experience, we streamline the entire facility development process.”



Proven track record and expertise in facility design and engineering

From years of experience, Samsung Biologics has refined its facility design methodology to minimize inefficiencies, reduce costs, and shorten project timelines. Our comprehensive strategy encompasses all facility development phases—from design and construction to operational readiness—ensuring each manufacturing site is ready to efficiently produce high-quality biopharmaceutical products.


Samsung Biologics successfully completed four large-scale plants, demonstrating a strong ability to manage complex projects effectively. The company is currently building Plant 5, the first facility of Bio Campus II, whichwill be operational by April 2025. The construction timeline is expected to be approximately 30% shorter than the 35 months taken to complete Plant 3, which has the same capacity. The shortened timeline underscores the company’s expertise and commitment to expanding manufacturing capabilities to meet diverse and immediate client needs.


plant1(30kL) : 25months, plant2(154kL) : 29months, plant3(180kL) : 34months, plant4(240kL) : 31months, plant5(180kL | Operational in April 2025) : 24months


Advanced engineering and estimation tools are crucial for meticulously planning facility development, including material and utility requirements, project timelines, and cost estimates. Using these tools and a project management information system for real-time management, Samsung Biologics significantly reduced the risk of cost overruns and delays, allowing for efficient resource allocation, benefiting the company and our clients.


Samsung Biologics continuously improves facility design, construction, and validation methodologies. Each new plant implements best practices and the latest regulatory requirements, optimized for operational excellence. The Engineering, Procurement, Construction, and Validation(EPCV) Team uses historical data from past projects for feasibility studies, gap analyses, and capital expenditure estimations to deliver customized solutions that meet clients’ needs.

 


Innovative strategies for enhancing efficiency

Samsung Biologics will adopt the standardized design at Bio Campus II, starting with Plant 5, to enable seamless scaling across multiple projects. This modular manufacturing model will accelerate construction timelines, enhance operational efficiency, and allow for agile adaptation to varying project requirements. By replicating proven designs and processes, Samsung Biologics can scale operations efficiently while maintaining the highest standards of quality and reliability. 


 

To be more flexible and efficient, Samsung Biologics employs an optimized downstream processing strategy that enables the simultaneous processing of multiple batches or different products. This is especially efficient for complex molecules or products that require longer processing times. Minimizing bottlenecks and ensuring continuous operation enables agile responses to changing production demands, maximizing throughput while ensuring quality and speed to market for clients.


“Having manufactured thousands of batches and developed hundreds of products, we have built a robust knowledge base that helps us anticipate challenges and develop cost-effective solutions,” explains Yujin Kim, an engineer in our Engineering Planning Group at Samsung Biologics. “Our focus on continuous improvement and innovation ensures that we are always advancing our capabilities to better support clients.” 

 


Commitment to quality and client success

Samsung Biologics emphasizes quality excellence as well as client satisfaction, and we continue to build on our facility development capabilities to exceed industry standards. The company is committed to providing clients with the utmost flexibility and reliability so they can quickly bring life-saving medicines to patients worldwide.


Samsung Biologics remains steadfast in its commitment to enhance manufacturing capabilities and provide innovative technological solutions. Additionally, the company will closely monitor its clients’ diverse needs and evolving market trends for timely capacity expansion and tailored services.


For more information about Samsung Biologics’ biomanufacturing capabilities, please contact us

 

Related contents

Samsung BIO Insight Accelerating success in biologics manufacturing | Tech transfer

Samsung BIO Insight Scaling Up Quality and Flexibility with Trusted Partnership

Brochure Plant 5

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION